Mebufotenin is under clinical development by GH Research and currently in Phase I for Unspecified Psychiatric Disorders.

Joe Rogan recently had former Texas governor Rick Perry and Kentucky Opioid Commission chairman W. Bryan Hubbard over in his podcast, the Joe Rogan Experience.

GH-002 is under clinical development by GH Research and currently in Phase I for Unspecified Neurologic Disorders.

5-Methoxy-N,N-dimethyltryptamine (5-MeO–DMT) has demonstrated submicromolar binding affinity across most serotonin receptor subtypes expressed in the CNS, with about 300-fold selectivity for human ...

A fully immersive wellness retreat can be hugely therapeutic. It was for 43-year-old life and business coach Lynda Williams, ...

HC Wainwright reiterated their buy rating on shares of GH Research (NASDAQ:GHRS – Free Report) in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a $40.00 ...

As the body of research grows around the potential promise of psychedelic medications in psychiatry, many questions and challenges remain.  The January issue of the American Journal of Psychiatry ...

Ketamine, a hallucinogenic drug approved as an anesthetic, has been used to treat adults with depression, PTSD and other conditions, and studied in youth with depression.

The money is also earmarked for a phase 1 dose-ranging study on an intranasal formulation of 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), a psychedelic compound found in plants and at least one ...

N-dimethyltryptamine (5-MeO-DMT) heading for phase 2 studies in depression and AUD in combination with psychotherapy. SUNHA candidate dropped There's also been some consolidation of Beckley's own ...

The report from Nevada’s Psychedelic Medicines Working Group notes that research increasingly indicates that treatment with substances such as psilocybin, 5-MeO-DMT, mescaline and ibogaine may improve ...